| 摘要 |
A type 2 helper T cell-selective immune response inhibitor of formula (I), the tautomer or a salt of the purine derivative, wherein; R2 is hydrogen or a C1-14 hydrocarbon group in which -CH2- not directly bound to the purine skeleton and CH2 in -CH3 not directly bound to the purine skeleton may be substituted by carbonyl, sulfonyl, -O- or -S-; =CH2 may be substituted by =O or =S; C-H in -CH2- not directly bound to the purine skeleton, C-H in -CH3- not directly bound to the purine skeleton, C-H in >CH- not directly bound to the purine skeleton, C-H in =CH- not directly bound to the purine skeleton and C-H in =CH2 may be substituted by N, C-halogen or C-CN; R6 is hydroxyl, amino or amino which is mono- or di-substituted by a C1-10 hydrocarbon group(s); R8 is hydroxyl, mercapto, C1-18 acyloxy or C1-19 hydrocarbon group-substituting oxycarbonyloxy; and R9 is a C1-14 hydrocarbon group in which -CH2- not directly bound to the purine skeleton and CH2 in -CH3 not directly bound to the purine skeleton may be substituted by carbonyl, sulfonyl, -O- or -S-, =CH2 may be substituted by =O or =S; C-H in -CH2- not directly bound to the purine skeleton, C-H in -CH3- not directly bound to the purine skeleton, C-H in >CH- not directly bound to the purine skeleton, C-H in =CH- not directly bound to the purine skeleton and C-H in =CH2 and C-H in CH may be substituted by N, C-halogen or C-CN. The type 2 helper T cell selective immune response inhibitor enhances the immune response on the type 1 helper T cell side and simultaneously inhibits the immune response on the type 2 helper T cell side. The purine derivatives are used as the active ingredient of pharmaceutical compositions in the treatment of allergic or autoimmune diseases.
|
